222 related articles for article (PubMed ID: 18318660)
1. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Andersen LM; Wind T; Hansen HD; Andreasen PA
Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
[TBL] [Abstract][Full Text] [Related]
2. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs.
Hosseini M; Jiang L; Sørensen HP; Jensen JK; Christensen A; Fogh S; Yuan C; Andersen LM; Huang M; Andreasen PA; Jensen KJ
Mol Pharmacol; 2011 Oct; 80(4):585-97. PubMed ID: 21719463
[TBL] [Abstract][Full Text] [Related]
4. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
6. Engineering bidentate macromolecular inhibitors for trypsin and urokinase-type plasminogen activator.
Yang SQ; Craik CS
J Mol Biol; 1998 Jun; 279(4):1001-11. PubMed ID: 9642077
[TBL] [Abstract][Full Text] [Related]
7. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
8. Dissecting and designing inhibitor selectivity determinants at the S1 site using an artificial Ala190 protease (Ala190 uPA).
Katz BA; Luong C; Ho JD; Somoza JR; Gjerstad E; Tang J; Williams SR; Verner E; Mackman RL; Young WB; Sprengeler PA; Chan H; Mortara K; Janc JW; McGrath ME
J Mol Biol; 2004 Nov; 344(2):527-47. PubMed ID: 15522303
[TBL] [Abstract][Full Text] [Related]
9. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
[TBL] [Abstract][Full Text] [Related]
10. A cyclic peptidic serine protease inhibitor: increasing affinity by increasing peptide flexibility.
Zhao B; Xu P; Jiang L; Paaske B; Kromann-Hansen T; Jensen JK; Sørensen HP; Liu Z; Nielsen JT; Christensen A; Hosseini M; Sørensen KK; Nielsen NC; Jensen KJ; Huang M; Andreasen PA
PLoS One; 2014; 9(12):e115872. PubMed ID: 25545505
[TBL] [Abstract][Full Text] [Related]
11. Interconversion of active and inactive conformations of urokinase-type plasminogen activator.
Liu Z; Kromann-Hansen T; Lund IK; Hosseini M; Jensen KJ; Høyer-Hansen G; Andreasen PA; Sørensen HP
Biochemistry; 2012 Oct; 51(39):7804-11. PubMed ID: 22950516
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities.
Di Giusto DA; Sutherland AP; Jankova L; Harrop SJ; Curmi PM; King GC
J Mol Biol; 2005 Nov; 353(5):1069-80. PubMed ID: 16214170
[TBL] [Abstract][Full Text] [Related]
13. Structural Principles in the Development of Cyclic Peptidic Enzyme Inhibitors.
Xu P; Andreasen PA; Huang M
Int J Biol Sci; 2017; 13(10):1222-1233. PubMed ID: 29104489
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Jankun J; Keck RW; Skrzypczak-Jankun E; Swiercz R
Cancer Res; 1997 Feb; 57(4):559-63. PubMed ID: 9044824
[TBL] [Abstract][Full Text] [Related]
15. Selection of High-Affinity Peptidic Serine Protease Inhibitors with Increased Binding Entropy from a Back-Flip Library of Peptide-Protease Fusions.
Sørensen HP; Xu P; Jiang L; Kromann-Hansen T; Jensen KJ; Huang M; Andreasen PA
J Mol Biol; 2015 Sep; 427(19):3110-22. PubMed ID: 26281711
[TBL] [Abstract][Full Text] [Related]
16. Nonproteolytic induction of catalytic activity into the single-chain form of urokinase-type plasminogen activator by dipeptides.
Bøtkjaer KA; Byszuk AA; Andersen LM; Christensen A; Andreasen PA; Blouse GE
Biochemistry; 2009 Oct; 48(40):9606-17. PubMed ID: 19705874
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-type plasminogen activator.
Crippa MP
Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
[TBL] [Abstract][Full Text] [Related]
18. Distinctive binding modes and inhibitory mechanisms of two peptidic inhibitors of urokinase-type plasminogen activator with isomeric P1 residues.
Jiang L; Zhao B; Xu P; Sørensen HP; Jensen JK; Christensen A; Hosseini M; Nielsen NC; Jensen KJ; Andreasen PA; Huang M
Int J Biochem Cell Biol; 2015 May; 62():88-92. PubMed ID: 25744057
[TBL] [Abstract][Full Text] [Related]
19. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
[TBL] [Abstract][Full Text] [Related]
20. Isolation and characterization of an inhibitory human monoclonal antibody specific to the urokinase-type plasminogen activator, uPA.
Sgier D; Zuberbuehler K; Pfaffen S; Neri D
Protein Eng Des Sel; 2010 Apr; 23(4):261-9. PubMed ID: 20086040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
